Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events.

Methods

The study was situated in a single academic medical center. The primary analysis evaluated whether exposure to an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls matched by age, a history of cardiovascular events, and cancer type. In a second design, a case-crossover analysis was performed with an at-risk period defined as the 2-year period after and the control

SUBMITTER: Drobni ZD 

PROVIDER: S-EPMC7736526 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature